CD274 and neoplasm: The SH-NPs and anti-PD-L1 synergistic treatment group significantly reduced the proportion of MDSCs, outperforming the single SH-NPs treatment group, and mitigated the immunosuppressive tumor microenvironment (Figure 4o and Figure S9).